Skip to main content
. 2022 Mar 2;2022(3):CD002795. doi: 10.1002/14651858.CD002795.pub3

Comparison 5. Dopamine beta‐hydroxylase inhibitors versus placebo.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
5.1 Drop‐out rate due to treatment emergent adverse effects 1   Risk Ratio (M‐H, Random, 95% CI) Subtotals only
5.1.1 Dropout rate 1 91 Risk Ratio (M‐H, Random, 95% CI) 1.10 [0.77, 1.58]
5.2 Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms 1   Mean Difference (IV, Random, 95% CI) Subtotals only
5.2.1 CAPS: Total score 1 86 Mean Difference (IV, Random, 95% CI) ‐5.27 [‐16.72, 6.18]
5.2.2 CAPS subscale: Re‐experiencing/intrusion 1 86 Mean Difference (IV, Random, 95% CI) 2.63 [‐1.67, 6.93]
5.2.3 CAPS subscale: Avoidance/numbing 1 86 Mean Difference (IV, Random, 95% CI) 0.58 [‐4.57, 5.73]
5.2.4 CAPS subscale: Hyperarousal 1 86 Mean Difference (IV, Random, 95% CI) 2.05 [‐1.82, 5.92]
5.3 Drop‐out rate due to any cause 1   Risk Ratio (M‐H, Random, 95% CI) Subtotals only
5.3.1 Dropout rate 1 100 Risk Ratio (M‐H, Random, 95% CI) 1.39 [0.64, 3.00]